Companies / G1 Therapeutics, Inc.
G1 Therapeutics, Inc.
GTHXCIK 1560241
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Velleca Mark A. Director | Sell Open-market sale | Common Stock | $1.01M | -80K -40.82% | 116,000 | medium |
| Jan 3, 2022 | Bailey John E. (Jack) Jr. CEO | Sell Open-market sale | Common Stock | $355.3K | -34K -12.77% | 233,208 | medium |
| Mar 2, 2021 | Malik Rajesh Executive | Sell Open-market sale | Common Stock | $344.2K | -15K -25.73% | 43,300 | medium |
| Apr 22, 2021 | Malik Rajesh Executive | Sell Open-market sale | Common Stock | $331.1K | -15K -25.73% | 43,300 | medium |
| Mar 23, 2021 | Malik Rajesh Executive | Sell Open-market sale | Common Stock | $329.1K | -15K -25.73% | 43,300 | medium |
| Jan 22, 2021 | Malik Rajesh Executive | Sell Open-market sale | Common Stock | $309.6K | -15K -27.17% | 40,200 | medium |
| Feb 16, 2021 | Velleca Mark A. Director | Sell Open-market sale | Common Stock | $290.0K | -8K -15.98% | 43,723 | medium |
| Sep 13, 2022 | Malik Rajesh Executive | Sell Open-market sale | Common Stock | $282.7K | -18K -19.74% | 73,207 | medium |